Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Receivables - Other (2018 - 2022)

Historic Receivables - Other for Ani Pharmaceuticals (ANIP) over the last 5 years, with Q4 2022 value amounting to $5.0 million.

  • Ani Pharmaceuticals' Receivables - Other changed N/A to $5.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $5.0 million, marking a year-over-year change of. This contributed to the annual value of $5.0 million for FY2022, which is N/A changed from last year.
  • Per Ani Pharmaceuticals' latest filing, its Receivables - Other stood at $5.0 million for Q4 2022.
  • Ani Pharmaceuticals' 5-year Receivables - Other high stood at $5.0 million for Q4 2022, and its period low was $14000.0 during Q3 2018.
  • For the 4-year period, Ani Pharmaceuticals' Receivables - Other averaged around $581400.0, with its median value being $100000.0 (2018).
  • Over the last 5 years, Ani Pharmaceuticals' Receivables - Other had its largest YoY gain of 61428.57% in 2019, and its largest YoY loss of 0.0% in 2019.
  • Over the past 4 years, Ani Pharmaceuticals' Receivables - Other (Quarter) stood at $100000.0 in 2018, then changed by 0.0% to $100000.0 in 2019, then changed by 0.0% to $100000.0 in 2020, then surged by 4900.0% to $5.0 million in 2022.
  • Its Receivables - Other was $5.0 million in Q4 2022, compared to $100000.0 in Q3 2020 and $100000.0 in Q2 2020.